2026 Interim report
Filed with HKEX · Stock code 2496 · · 55 pages · English
2 Definitions 6 Corporate Information 8 Financial Summary 9 Management Discussion and Analysis 20 Corporate Governance and Other Information Condensed Consolidated Statement of Profit or Loss and 33 Other Comprehensive Income 34 Condensed Consolidated Statement of Financial Position 36 Condensed Consolidated Statement of Changes in Equity 37 Condensed Consolidated Statement of Cash Flows 38 Notes
Wuhan YZY Biopharma Co., Ltd. on 6ix
Earlier from Wuhan YZY Biopharma
Later from Wuhan YZY Biopharma
- Update on the qualification of joint company secretary and resignation of joint company secretary and change of process agent
- Delay in despatch of circular in relation to (1) connected transaction in respect of the proposed issue of new domestic shares under Specific mandate; (2) application for Whitewash Waiver; and (3) proposed amendments to the articles of association
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement the first patient dosed in phase i clinical trial of Y225 for treatment of hemophilia a
- Closure of register of members for extraordinary general meeting
Follow Wuhan YZY Biopharma into a list and get an email when it puts out news.
Follow Wuhan YZY Biopharma